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Abstract
Background: Currently available chronic myeloid leukaemia (CML) survival reports have originated from more
affluent countries. Herein we report the entire country data on incidence and survival of CML, as well as penetrance
of tyrosine kinase inhibitors (TKIs) in Lithuania.
Methods: We analyzed all patients (N = 601) from the national haematological disease monitoring system who
were diagnosed with CML between 2000 and 2013. Crude (CR) and age-standardized (weighted) (ASW(R))
incidence and mortality rates, as well as 1-, 5-, and 10-year relative survival rates (RSR) were calculated. Information
on TKI penetration is also reported.
Results: Throughout the entire 2000–2013 period the median age at diagnosis of CML patients was 62 years. The
respective incidence and mortality CRs were 1.28 and 0.78, both characterized by decreasing trends over the observation
period. A 5-year RSR increased from 0.33 [95 % CI, 0.27–0.40] in 2000–2004 to 0.55 [95 % CI, 0.47–0.63] in 2005–2009.
However, the respective 5-year RSRs for patients aged 65–74 and ≥75 were only 0.33 [95 % CI, 0.24–0.42] and
0.18 [95 % CI 0.07–0.23] during the entire study period. TKI penetrance for CML patients grew from 1.5 % in
2000–2004 to 30.6 % in 2005–2009 and 69.1 % in 2010–2013. TKI penetrance was low in the older age groups
(60 % for the 65–74 and 19 % for the ≥75 patient group, in 2010–2013).
Conclusion: Relative CML survival in Lithuania steadily improved and paralleled the increase in TKI treatment
availability. Patients above 64 years rarely received TKIs and their relative survival remained low throughout the
observation period. The latency of TKI availability may have influenced the survival trends.
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Background
The approval of Imatinib mesylate in 2001 [1] and there-
after emergence of second generation Bcr-Abl1 inhibi-
tors have transformed Chronic Myeloid Leukaemia
(CML) from deadly to readily treatable cancer [2, 3].
IFNα and chemotherapy were rapidly replaced by ima-
tinib as a mainstay treatment of CML, after clinical trial
data demonstrated the treatment effect that few cancer
treatments have shown before [4–6].
Although in some patients tyrosine kinase inhibitors
(TKIs) may cure CML, the discontinuation of imatinib
treatment in prolonged molecular remission usually
leads to the molecular relapse of the disease [7]. There-
fore to acquire a survival benefit, most of CML patients
need to stay on TKIs for the rest of their life. With ever
expanding CML patient population the financial sustain-
ability of expensive Bcr-Abl1 inhibitors has been debated
even in economically well-established countries [8].
Current cost-effectiveness and cost-utility analyses are
based on data from clinical trials, which delineate strict
patient inclusion criteria and provide rigorously con-
trolled treatment regimens at university hospitals [9, 10].
But in real life patients and treatment quality in different
centers may be more variable, thus clinical trials may
not always accurately reflect the treatment efficacy at a
country-wide population level [11]. Population studies
readily address these challenges and can accurately de-
scribe the incidence, prevalence and real-life survival of
target disorder.
Currently available population CML survival data has
largely originated from economically well-established
countries [2, 3, 12–15]. However, some of CML survival
population studies rely exclusively on regional registries
linked to haematological specialty centers, rather than
national cancer registries, and therefore are susceptible
to referral and selection bias [3, 14]. Complete popula-
tion reports minimize the risk of selection bias, but en-
tire country population CML incidence and survival
reports are currently accessible for Sweden and United
Kingdom only [2, 12, 13].
The transitional nature of Lithuania’s economy has
limited the availability of cancer medicines under patent:
imatinib became partially available in 2005 and fully
available only in 2011. In this study we report an unse-
lected entire country population data on CML incidence,
survival and TKI penetrance in Lithuania from 2000 to
2013. We also aim to compare the CML survival differ-
ences between countries due to differences in the avail-
ability of the innovative treatment.
Methods
Lithuanian HESS registry
Lithuania has a national haematological disease monitor-
ing system (HESS), which collects data from 2000 and
covers the entire country, with a population of 3 million.
Patients with haematological malignancies are managed
in 5 centres across the country and all physicians and
pathologists are obliged to report all newly diagnosed
CML cases to HESS registry. HESS contains data on age,
sex, ICD-10 code, date of diagnosis, clinical symptoms,
laboratory test, risk group, treatment, Ph and BCR-ABL
status (both mandatory from 2010) of CML. Eastern
Cooperative Oncology Group (ECOG) performance
score and CML phase at presentation were collected
from 2010. Through unique personal ID, HESS is also
linked to the national death registry, which allows fur-
ther validation of data. All Lithuanians are covered by
national healthcare insurance and haematological dis-
eases are treated in public healthcare system. Therefore
underreporting to HESS registry is unlikely. All patients,
who were diagnosed with CML (ICD-10 code 92.1) be-
tween January 1st 2000 and December 31st 2013, were
entered into the study. There was no age restriction or
other exclusion criteria. The study was conducted ac-
cording to the declaration of Helsinki and was approved
by the Lithuanian Bioethics Committee, which also
waived the need for informed consent.
Statistical methods
Descriptive statistics were used to analyze patients’ dem-
ography. Student-t or Mann-Whitney-Wilcoxon tests
were used to evaluate the differences between the two
independent groups. The differences between independ-
ent categorical data groups were evaluated by Fisher
exact test.
Age was categorized in 10 subgroups (Additional file 1:
Table S1) for incidence analysis and 5 subgroups (<45, 45–
54, 55–64, 65–74 and ≥75) for survival analysis. Crude and
age standardized rates according to world population (CR
and ASR (W), respectively) were calculated for incidence,
prevalence and mortality. CR was represented as the num-
ber of patients per 100 000 inhabitants per year in
Lithuania [16]. ASR (W) was defined as a weighted mean
of the age-specific rates [17]; the weights were taken from
the standard world population [18]. Incidence rate was de-
fined as the number of new CML cases that occurred dur-
ing a given time period [16]. Mortality rate was defined as a
number of deaths from any cause during a given time
period [16].
Relative survival rate (RSR) was defined as observed
survival in CML group divided by the expected survival
of a comparable group from general population [19].
Observed and expected survival were calculated using
Kaplan-Meier [20] and Ederer II [21] method, respect-
ively. One-, five- and ten-year RSRs with 95 % confi-
dence intervals (95 % CI) were estimated. Survival time
was calculated as the time from the date of diagnosis to
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death; 31st of December 2014 was set as censoring date
for alive patients.
All statistics were performed by Statistical Analysis
System (SAS) package version 9.2. A two-tailed p-value
less than 0.05 was considered significant.
Results
Study population
From January 1st 2000 to December 31st 2013, 601 pa-
tients newly diagnosed with CML were included in the
HESS registry. None of them were lost to follow-up. The
median follow-up time for alive patients was 74 months
(range 13–172). The genetic or cytogenetic confirmation
of Ph + and/or BCR-ABL1 fusion status was available for
33 % of CML diagnoses made in 2000–2004, 83 % in
2005–2009 and 82 % in 2010–2013 period. Throughout
the 14 year period male to female sex ratio was 1.09 with
median age at diagnosis of 62 (range 14–93) and 63
(range 5–94) (p = 0.170), respectively. Older people were
more likely to suffer from CML: 47 % of all CML cases
were older than 65 years, although only 16 % of the
Lithuanian population was older than 65 years (Table 1).
The median age at diagnosis was 65 years at 2000–2004,
63 at 2005–2009 and 58 at 2010–2013 (p = 0.288). Dur-
ing the 2010–2013 period the share of CML diagnoses
in people under 65 was higher (64 %) compared to two
previous periods (49 % in 2000–2004, 53 % in 2005–
2009) (p = 0.031).
Incidence
The CR and ASR (W) of CML in Lithuanian population
during the period of 2000–2013 was, accordingly, 1.28
(1.44 in males, 1.15 in females) and 0.88 (1.04 in males,
0.76 in females) (Table 2). Over the 14 year period of
monitoring both metrics of CML incidence in Lithuania
have steadily decreased. CR fell from 1.51 in 2000–2004
to 1.03 in 2010–2013. CML incidence increased with
age. It was the lowest in the 0–14 age group (CR = 0.04)
and the highest in ≥75 age group (CR = 4.36) (Additional
file 1: Table S1). Although overall CML incidence was
higher in men, greater male preponderance became evi-
dent only above the age of 60.
Accelerated phase, blast crisis and performance status
During the 2010–2013 period, accelerated phase (AP)
and blast crisis (BC) data was available for 102 (81 %)
and ECOG performance status for 92 (73 %) of newly di-
agnosed patients. At presentation 86 % were in CP, 12 %
in AP and 2 % in BC. The median follow-up time for
2010–2013 cohort was 37 months (range 13–60
months). 1 patient progressed from CP to AP and 2
patients from AP to BC. None of the patients present-
ing with AP progressed into BC. At presentation, 92 %
of patients below 75 years had ECOG performance
status score of 0–1 (Additional file 1: Table S9). Only
22 % of ≥75 age group had ECOG 0–1.
Mortality
Throughout the entire 2000–2013 period the average
mortality CR and ASR (W) were 0.78 (range 0.26–
1.08) and 0.46 (range 0.13–0.72), respectively. The
average mortality CR and ASR (W) decreased from
0.82 to 0.69 and from 0.47 to 0.38, respectively, com-
paring 2000–2004 and 2010–2013 periods. Although
there was no significant difference in crude male and
female mortality rates (p = 0.095), men had a higher
overall ASR (W) mortality (p = 0.014) (Table 2). Older
age was a strong factor for higher mortality CR
throughout all time periods (p < 0.001 for all periods)
(Additional file 1: Table S4).
Survival trends
The RSR improved with every calendar period of treat-
ment. Overall, 1-, 5- and 10-year RSRs were 0.72, 0.49
and 0.36, respectively. RSR trends between males and fe-
males were similar throughout the entire follow-up
period (p = 0.697) (Table 3). Age was an important pre-
dictor of RSR, with younger patients having significantly
better RSR than elderly. 1-year RSR has markedly in-
creased from 0.61 [95 % CI, 0.55–0.67] in 2000–2004 to
0.81 [95 % CI, 0.74–0.86] in 2005–2009, but plateaued at
0.81 [95 % CI, 0.74–0.86] during the 2010–2013 period
(Table 3).
Table 1 CML demographics in Lithuania in 2000–2013
Demographics Calendar period Total
2000–2004 2005–2009 2010–2013
N % N % N % N %
Total 263 44 212 35 126 21 601 100
Age, years
Median 65 63 58 62
Range 5–94 9–90 17–94 5–94
0–44 60 23 44 21 35 28 139 23
45–54 28 11 36 17 19 15 83 14
55–64 41 16 31 15 26 21 98 16
65–74 78 30 49 23 23 18 150 25
75+ 56 21 52 25 23 18 131 22
Gender
Male 139 53 108 51 66 52 313 52
Female 124 47 104 49 60 48 288 48
Hematopoietic stem cell transplantation
Allogeneic 6 2 14a 7 7b 6 27 4
a2 patients with double haematopoietic stem cell transplant (HSCT)
b1 patient with double HSCT
Beinortas et al. BMC Cancer  (2016) 16:198 Page 3 of 10
A 5-year CML RSR increased from 0.33 [95 % CI,
0.27–0.40] in 2000–2004 to 0.55 [95 % CI, 0.47–0.63] in
2005–2009 period in Lithuania. All patient groups, but
those above 75, have demonstrated an increase in 5-year
RSR. A 10-year RSR for the overall cohort was 0.36
[95 % CI, 0.31–0.42]. Figure 1 demonstrates how cumu-
lative RSR changed with every calendar period. Interest-
ingly, during the 2010–2013 period RSR started to
increase beyond 2 years after the diagnosis.
Relative survival rate was calculated by diving the ob-
served survival ratio by the expected survival ration of
age-specific general population
Treatment
Figure 2 describes the TKI availability for CML patients
in different calendar periods. TKI penetrance for CML
patients grew from 1.5 % in 2000–2004 to 30.6 % in
2005–2009 and 69.1 % in 2010–2013. Imatinib was the
only first line TKI for all study periods, which was
guided by the national reimbursement policy. The in-
creased availability of TKI treatment was largely limited
to younger patient groups. In 2005–2009 49.5 % and in
2010–2013 81.0 % of patients younger than 65 were
treated with TKIs. Until 2009 not a single patient ≥75
was treated with TKIs and even in the most recent
period (2010–2013) the penetrance of TKIs in ≥75 pa-
tient group remained low (18.6 %). Across all three pe-
riods, 4 % of patients were treated with hematopoietic
stem cell transplantation (4 %) (Table 1).
Discussion
Imatinib generics are scheduled to enter US and European
markets in early 2016 and the need for high quality
population-level data to support better policy making is
particularly increased [9, 22]. However, population-level re-
ports reflecting the efficacy of CML treatment in TKI era
are still scarce. Several available studies stem from haema-
tology center-based registries or regional registries. Al-
though valuable, they ignore the impact of out-of-region
referral to treatment center and practice at local hospitals
on presented data [14]. Entire country registry-based
studies avoid these shortcomings, but cannot provide more
detailed outcomes and have no control over the treatment
and monitoring of the disease. Here we present one of few
national registry CML epidemiology reports covering the
population of the entire country. In addition, this is the first
study demonstrating the CML treatment outcome inequal-
ities between countries, owing to differences in the avail-
ability of the innovative treatment.
The age distribution of CML cases in Lithuania was
virtually identical to the European averages, as summa-
rized in the EUTOS population-based registry and HAE-
MACARE project reports [22, 23]. CML incidence CR in
Lithuania was not stable throughout the observation
period and decreased steadily from 1.51 in 2000–2004
period to 1.03 in 2010–2013. Cumulative CML incidence
seen during the entire 2000–2013 period (CR 1.28) was
slightly higher than CR of 1.10 seen in 48 European can-
cer registries in 2000–2002 and CR of 0.99 reported
from EUTOS registry in 2008–2012 [24]. Meanwhile, re-
ports from Swedish and UK registries both demon-
strated even lower cumulative annual CML incidence
(CR of 0.9) [12, 25]. Interestingly, considerably higher in-
cidence metrics are seen in USA, where annual cumula-
tive CML incidence CR has been consistently reported
at 1.7–1.8 per 100000 population [26, 27].
Pathological and clinical diagnosis alone is known
to sometimes misdiagnose Ph negative myeloprolifer-
ative neoplasias as CML [22]. BCR-ABL negative
CML incidence was not available from the Lithuanian
registry, but was previously reported to constitute 0.6 % of
all CML cases in USA, 2 % in Italy and 4 % in France
[3, 28, 29]. In Lithuanian HESS registry only a propor-
tion of CML diagnoses were genetically confirmed, es-
pecially during the earliest study period. It is the
drawback of our study, which probably explains the
decreasing CML incidence over years, as share of gen-
etically confirmed CML diagnoses increased. There-
fore CR of 1.03 from the most recent 2010–2013
period is likely to represent the most accurate value of
annual CML incidence in Lithuania. Likewise, a low
percentage of genetically confirmed CML cases are
Table 2 CML epidemiology in Lithuania in 2000–2013
Epidemiology Calendar period
2000–2004 2005–2009 2010–2013 2000–2013
Male Female All Male Female All Male Female All Male Female All
Incidence rate
CR 1.72 1.34 1.51 1.37 1.15 1.25 1.17 0.91 1.03 1.44 1.15 1.28
ASR (W) 1.20 0.87 1.00 1.00 0.72 0.86 0.88 0.65 0.75 1.04 0.76 0.88
Mortality rate
CR 0.98 0.68 0.82 0.83 0.80 0.82 0.82 0.58 0.69 0.89 0.69 0.78
ASR (W) 0.62 0.38 0.47 0.61 0.46 0.52 0.52 0.29 0.38 0.59 0.38 0.46
ASR (W) age-standardized (weighted) rate, CR crude rate
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Table 3 One-, five- and ten-year RSR % of CML in Lithuania
Population Calendar Period
2000–2004 2005–2009 2010–2013 2000–2013
RSR 95 % CI RSR 95 % CI RSR 95 % CI RSR 95 % CI
1 year RSR
All
0–44 years 0.94 0.83–0.98 0.91 0.78–0.97 0.97 0.82–1.00 0.94 0.88–0.97
45–64 years 0.72 0.60–0.81 0.89 0.79–0.95 0.94 0.82–0.99 0.84 0.78–0.89
65–74 years 0.43 0.31–0.54 0.83 0.68–0.92 0.67 0.44–0.84 0.59 0.51–0.67
75+ years 0.35 0.22–0.49 0.57 0.41–0.71 0.49 0.26–0.69 0.46 0.37–0.55
Overall 0.61 0.55–0.67 0.81 0.74–0.86 0.81 0.74–0.86 0.72 0.69–0.76
Male
0–44 years 0.91 0.73–0.91 0.85 0.64–0.94 0.96 0.72–1.00 0.90 0.81–0.95
45–64 years 0.70 0.52–0.82 0.90 0.72–0.97 1.00 - 0.84 0.74–0.90
65–74 years 0.39 0.24–0.53 0.81 0.59–0.93 0.81 0.46–0.96 0.58 0.46–0.68
75+ years 0.28 0.11–0.48 0.54 0.30–0.75 0.43 0.16–0.70 0.41 0.28–0.54
Overall 0.58 0.49–0.66 0.79 0.70–0.87 0.85 0.73–0.93 0.71 0.65–0.76
Female
0–44 years 0.97 0.78–1.00 1.00 - 1.00 - 0.98 0.89–1.00
45–64 years 0.75 0.55–0.87 0.89 0.72–0.96 0.89 0.70–0.97 0.84 0.75–0.90
65–74 years 0.48 0.30–0.64 0.84 0.61–0.95 0.51 0.19–0.77 0.61 0.48–0.72
75+ years 0.41 0.23–0.59 0.59 0.38–0.76 0.56 0.20–0.84 0.51 0.38–0.62
Overall 0.65 0.55–0.73 0.82 0.73–0.89 0.80 0.67–0.89 0.74 0.68–0.79
5 year RSR
All
0–44 years 0.60 0.46–0.71 0.90 0.76–0.97 - - 0.77 0.69–0.84
45–64 years 0.42 0.30–0.54 0.70 0.57–0.81 - - 0.64 0.55–0.71
65–74 years 0.16 0.08–0.26 0.52 0.35–0.68 - - 0.33 0.24–0.42
75+ years 0.14 0.05–0.29 0.09 0.02–0.22 - - 0.14 0.07–0.23
Overall 0.33 0.27–0.40 0.55 0.47–0.63 N/R N/R 0.49 0.45–0.54
Male
0–44 years 0.53 0.34–0.70 0.83 0.61–0.94 - - 0.74 0.62–0.83
45–64 years 0.44 0.27–0.61 0.74 0.53–0.89 - - 0.66 0.53–0.77
65–74 years 0.14 0.05–0.28 0.50 0.27–0.73 - - 0.33 0.21–0.46
75+ years 0.14 0.02–0.39 0.16 0.03–0.45 - - 0.18 0.07–0.35
Overall 0.32 0.24–0.41 0.59 0.47–0.70 N/R N/R 0.51 0.44–0.58
Female
0–44 years 0.66 0.46–0.80 1.00 - - - 0.82 0.69–0.90
45–64 years 0.40 0.23–0.58 0.67 0.48–0.81 - - 0.61 0.49–0.72
65–74 years 0.18 0.07–0.34 0.53 0.30–0.74 - - 0.33 0.21–0.46
75+ years 0.14 0.04–0.34 0.05 0.00–0.21 - - 0.11 0.04–0.23
Overall 0.35 0.26–0.44 0.52 0.41–0.63 N/R N/R 0.48 0.41–0.55
10 year RSR
All
0–44 years 0.42 0.29–0.55 - - - - 0.60 0.48–0.70
45–64 years 0.29 0.18–0.42 - - - - 0.52 0.40–0.63
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seen in the SEER data and might underlie the observed
CML incidence discrepancies between USA and Europe
[22, 27]. In the latter only genetically confirmed CML
diagnoses are included in the EUTOS registry. As
much as 12 % of new CML diagnoses in Lithuania pre-
sented in the accelerated phase, whereas they com-
prised only 4 % of all new CML cases in Sweden and
5 % in Czech Republic and Slovakia [12, 14]. However,
phase at presentation data was available only for the
2010–2013 period and larger numbers will be needed
to draw a definitive conclusion of higher incidence of
AP-CML in Lithuania compared to other countries.
Introduction of imatinib mesylate as a first line ther-
apy has led to great improvements in prognosis for CML
patients. Treatment results in IRIS trial demonstrated a
89 % overall 5-year survival for patients aged 18–70 and
treated with imatinib as a first-line agent [30]. Similarly
high long-term survival rates were also demonstrated in
centers of excellence for CML care [31, 32]. Since oral
administration of imatinib significantly reduced the
complexity of care for CML patients, the treatment may
be decentralized and provided outside teaching hospitals.
However, a study by Lauseker et al. found that in
Germany outcomes for patients treated outside teaching
hospitals are markedly inferior to those treated in aca-
demic centers [33]. In Sweden academic center catch-
ment areas also had a tendency to give superior CML
treatment results to other regions, though not at a statis-
tically significant level [12]. Thus national survival aver-
ages are likely to be worse than survival reports from
sole specialty centers, or regional registries, based
around tertiary haematology center.
In Lithuania, country with 3 million inhabitants, CML
is treated in 5 hospitals, 2 of which are teaching
Table 3 One-, five- and ten-year RSR % of CML in Lithuania (Continued)
65–74 years 0.08 0.03–0.18 - - - - 0.19 0.09–0.32
75+ years - - - - - - - -
Overall 0.21 0.16–0.27 N/R N/R N/R N/R 0.36 0.31–0.42
Male
0–44 years 0.38 0.21–0.56 - - - - 0.58 0.41–0.72
45–64 years 0.33 0.17–0.52 - - - - 0.53 0.37–0.69
65–74 years 0.04 0.00–0.18 - - - - 0.11 0.01–0.36
75+ years - - - - - - - -
Overall 0.21 0.14–0.30 N/R N/R N/R N/R 0.37 0.28–0.46
Female
0–44 years 0.46 0.27–0.63 - - - - 0.63 0.45–0.76
45–64 years 0.25 0.11–0.42 - - - - 0.49 0.32–0.65
65–74 years 0.13 0.03–0.30 - - - - 0.24 0.12–0.39
75+ years - - - - - - - -
Overall 0.21 0.14–0.30 N/R N/R N/R N/R 0.36 0.28–0.44
Fig. 1 Relative survival rate by period of diagnosis
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hospitals. Prior to TKI entry, CML patients in Lithuania
were treated with hydroxyurea and IFNα, while only oc-
casional eligible patient received a haematological stem
cell transplant (HSCT). 5-year RSR increased from 33 %
in 2000–2004 to 55 % in 2005–2009, when TKIs became
partially available in Lithuania. Recently EUROCARE-5
project reported haematological cancer RSRs for differ-
ent European regions [34]. Here Lithuania along with
Estonia, Slovakia, Poland and Bulgaria constituted the
Eastern Europe region. Throughout 2000–2004 and
2005–2009 periods, 5-year CML RSR in Lithuania
remained above the Eastern European registry averages,
at overall European average, but below the RSR averages
seen in Sweden (Table 4). Every age group 5-year RSR
averages also remained lower than those reported from
UK, USA and Girona province of Spain [13, 35, 36].
Unfortunately, UK data in Pulte et al. study may be
compounded by CML registration inaccuracies [37].
Smith et al. report demonstrates that the actual 5-year
RSR in UK is probably significantly higher (0.89 for
2004–2011 period) and no worse than CML RSR seen in
Sweden [36]. Similarly to other studies, the biggest
5-year RSR improvements in Lithuania were evident
in patient groups <75 [2, 3]. 1-year (RSR 0.46, 95 %
CI 0.37–0.55) and 5-year (RSR 0.14, 95 % CI 0.07–0.23)
RSR in patients ≥75 remained low throughout the entire
2000–2013 period.
Five-year RSR for patients newly diagnosed with
CML in 2010–2013 is not available yet, but cumulative
4-year RS for this period was >0.80. Relative survival
for this latest Lithuanian patient cohort is approaching
the 5-year RSR recorded in French cancer registries
(RSR 0.83 in 2000–2009) and Swedish national registry
(RSR 0.80 in 2001–2008) in the early years of TKI
utilization [2, 3]. Interestingly, the patient population
diagnosed with CML during the 2010–2013 period,
started showing an upward RSR trend two years after
the diagnosis. This finding is in line with results pub-
lished by Gambacorti-Passerini et al. who show that
people treated with imatinib and in cytogenic remis-
sion for >2 years, carry only 4.8 % annual overall mor-
tality, which is similar to matched general population
[38]. It is possible that imatinib has a long term car-
diovascular protective effect [39], though opposite
claims have also been published [40].
The emergence of effective treatment has also spar-
kled enthusiasm in standardizing the CML referral
pathways, formulating explicit treatment guidelines and
employing the newest molecular disease monitoring
2000-2004 2005-2009 2010-2013
0-44 yo 7% 62% 79%
45-54 yo 0% 55% 84%
55-64 yo 0% 22% 81%
65-74 yo 0% 7% 60%






















Fig. 2 Tyrosine kinase inhibitor penetrance for treatment of CML in Lithuania
Table 4 5-year RSR for CML patients from registry data stratified
by region of origin and time period
Source Time period 5 Year RSR % (95 % CI)
Europe 2000–2002 33.8 (32.2–35.4)
Sant et al. 2014 [34] 2003–2005 45.7 (43.9–47.5)
2006–2008 54.4 (52.5–56.2)
Eastern Europea 2000–2002 26.4 (22.4–30.6)
Sant et al. 2014 [34] 2003–2005 28.6 (25.0–32.4)
2006–2008 35.3 (30.9–39.7)
Sweden 2001–2008 80 (75–83)
Bjorkholm et al. 2011 [2]
Lithuania 2000–2004 33 (27–40)
Our data 2005–2009 55 (47–60)
aEastern Europe region: Lithuania, Estonia, Poland, Slovakia and Bulgaria
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and prognostication techniques, which have potentially
led to the improvement of CML patient care and sur-
vival. Yet TKI penetrance is probably the sole most
important determinant of CML survival on a country
level. In Lithuania the penetrance of TKI treatment
was largely determined by national reimbursement
policy. Owing to healthcare resource restrictions, here
patented cancer therapies have longer availability latency
than in Western Europe. While in multiple Western econ-
omies imatinib entered national CML treatment guidelines
as a first line CML treatment in 2001-2, imatinib became
partially available in Lithuania only in 2005. During the
2005–2009 period TKI treatment was reserved only for the
youngest patients: 58 % patients aged <55 and only
8 % patients ≥55 received TKIs. Only from 2011 all
newly diagnosed CML patients were funded to have
imatinib as a first line treatment, but even during the
2010–2013 period of CML diagnosis, in Lithuania only
69 % of patients were treated with TKIs.
A noteworthy study was recently published from an-
other less affluent country - Bosnia and Herzegovina –
demonstrating that many patients experience a delay in
receiving the TKI treatment and therefore have worse
cytogenetic and molecular remission rates [41]. Individ-
ual case TKI reimbursement system seen Bosnia func-
tioned in Lithuania between 2005 and 2011 and here the
argument that delay in administering TKIs could lead to
inferior outcomes is also valid.
Although excellent CML survival rates have been re-
ported from regional population databases in France and
UK, so far no other country has reported better entire
country population CML survival results than Sweden
[3, 12, 36]. Hoglund et al. data contradicts the criticism that
clinical trial treatment efficacy results cannot be expected
in general population [11]. With nearly complete CML
population coverage with TKIs, survival for chronic phase
CML patients aged ≤60 in Sweden was close to survival of
general population [12]. Since 2004 > 85 % CML patients
have been receiving TKIs as a first-line treatment in
Sweden [12]. A French report showed that 93 % of patients
diagnosed with CML during 2000–2009 period were
treated with TKIs [3]. Interestingly, in some countries TKI
availability is not a correlate of the economic output. Due
to loose regulations and easily available cheap imatinib ge-
nerics, some Pacific-Asian countries have even higher TKI
coverage than some Western countries that pay the full pat-
ented drug price [42].
Even during 2010–2013 period the accessibility of
TKIs for patients ≥75 was much smaller (18 %) than for
younger population (81 % of <65 years). Likewise, in
USA significantly fewer elderly patients, when compared
to younger patients, were given TKIs during the 2003–
2005 observation period, though these rates would have
certainly increased by now [43]. Meanwhile, Swedish
national registry report shows that during 2001–2008
period >80 % of CML patients aged ≥75 received TKIs
[12]. Overall CML survival, when treated with TKIs, was
shown to be more dependent on the number of comorbidi-
ties than on patient’s age [44]. Our data demonstrates that
patients ≥75 presenting with CML have markedly worse
ECOG performance status than younger patients and this
may underlie physicians’ decision to withhold the TKI treat-
ment. However, only 60 % of 65–74 year old CML patients,
who had much better performance status, were prescribed
imatinib. There may well be a bias among doctors to with-
hold the expensive treatment from elderly patients with a
view of reserving it for the younger. However, studies show
that elderly CML patients benefit from TKI treatment
nearly as much as younger patients and age has no object-
ive role as a selection criteria for the TKI treatment [45].
Conclusion
In Lithuania crude CML incidence matched the European
averages once strict genetic diagnostics criteria were imple-
mented. Relative CML survival improved from 2000–2004
to 2010–2013 period and was paralleled by the increasing
availability of TKI treatment. CML patients in Lithuania
had better relative survival than the Eastern European aver-
age, but lower than CML patients in more affluent coun-
tries, where TKI penetrance was higher. Patients above
75 years rarely received TKIs and their relative survival
remained low throughout the observation period.
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